Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Robert Litman, Dieter Naber, Lourdes Anta, Javier Martínez, Yuriy Filts & Christoph U Correll. (2023) Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Neuropsychiatric Disease and Treatment 19, pages 219-232.
Read now
Read now
Amal Abdel-Baki, Émile Poulin, Sofia Medrano, Paula Pires de Oliveira Padilha, Emmanuel Stip & Stéphane Potvin. (2023) Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study. International Journal of Psychiatry in Clinical Practice 27:1, pages 25-34.
Read now
Read now
Maria Paz Garcia-Portilla, Adolfo Benito Ruiz, Felisa Gómez Robina, Marta García Dorado & Paola María López Rengel. (2022) Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study. Expert Opinion on Pharmacotherapy 23:5, pages 629-638.
Read now
Read now
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Read now
Nan Li, Jian Min Zhuo, Ibrahim Turkoz, Maju Mathews, Yu Feng & Wilson Tan. (2019) A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opinion on Pharmacotherapy 20:16, pages 2033-2039.
Read now
Read now
Robin Emsley, Ludger Hargarter, Paul Bergmans, Boran Uglešić, Abdullah Cem Sengül, Antonino Petralia, Angelina Khannanova, Pierre Cherubin & Andreas Schreiner. (2017) Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2261-2269.
Read now
Read now
Tianmei Si, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews, Wilson Tan & Yu Feng. (2017) Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety. Expert Opinion on Pharmacotherapy 18:17, pages 1799-1809.
Read now
Read now
M. C. Mauri, A. Reggiori, S. Paletta, C. Di Pace & A. C. Altamura. (2017) Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. Expert Opinion on Drug Safety 16:3, pages 365-379.
Read now
Read now
Articles from other publishers (12)
John M Kane, Eran Harary, Roy Eshet, Orna Tohami, Mark Weiser, Stefan Leucht, Avia Merenlender-Wagner, Nir Sharon, Glen L DavisIIIIII, Mark Suett, Kelli R Franzenburg & Christoph U Correll. (2023) Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. The Lancet Psychiatry 10:12, pages 934-943.
Crossref
Crossref
Dilara Çirakman, Ersin Hatice Karslioğlu, Neşe Burcu Bal & Ali Çayköylü. (2023) The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia. International Clinical Psychopharmacology.
Crossref
Crossref
Qian Li, Xin Li, Chong Ye, Miaomiao Jia & Tianmei Si. (2023) Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis. CNS Drugs 37:8, pages 695-713.
Crossref
Crossref
Celso Arango, Andrea Fagiolini, Philip Gorwood, John M. Kane, Sergio Diaz-Mendoza, Navdeep Sahota & Christoph U. Correll. (2023) Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery. BMC Psychiatry 23:1.
Crossref
Crossref
Christoph U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre & Panagiotis Mavros. (2023) Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia 9:1.
Crossref
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Crossref
Hiroshi Kimura, Nobuhisa Kanahara & Masaomi Iyo. (2021) Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behavioural Brain Research 403, pages 113126.
Crossref
Crossref
Brianne Brown, Ibrahim Turkoz, Branislav Mancevski & Maju Mathews. (2019) Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Intervention in Psychiatry 14:4, pages 428-438.
Crossref
Crossref
Halise Devrimci-Ozguven, Murad Atmaca, Zeynep Baran, Cengiz Cengisiz, Cem Çinar, Atila Erol, Yasin Genç, Hasan Karadağ, Kamuran Karakülah, Umut Karasu, Mehmet Cemal Kaya, Emre Kizil, Halil Özcan, Ahmet Tiryaki, Alp Üçok, Cenk Varlik, Sila Menekşe Yazar & Mesut Yildiz. (2019) Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 39:6, pages 604-610.
Crossref
Crossref
Paola Bozzatello, Silvio Bellino, Irene Mancini, Luisa Sandei, Enrico Zanalda & Paola Rocca. (2018) Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. Clinical Drug Investigation 39:2, pages 169-178.
Crossref
Crossref
Valentina Corigliano, Anna Comparelli, Iginia Mancinelli, Benedetta Montalbani, Dorian A. Lamis, Antonella De Carolis, Denise Erbuto, Paolo Girardi & Maurizio Pompili. (2018) Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study. Schizophrenia Research and Treatment 2018, pages 1-7.
Crossref
Crossref
Hongyan Zhang, Ibrahim Turkoz, Jianmin Zhuo, Maju Mathews, Wilson Tan & Yu Feng. (2017) Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia. Advances in Therapy 34:11, pages 2503-2517.
Crossref
Crossref